Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
66.20    -1.80 (-2.65%)
Bid:
65.90
Ask:
66.70
Spread: 0.80 (1.214%)
Market Cap: £584.83m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Share buyback programme

8 Oct 2021 07:00

RNS Number : 4317O
IP Group PLC
08 October 2021
 

FOR RELEASE ON

08 October 2021

 

 

IP Group plc - Share buyback programme

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), the developer of intellectual property-based businesses, announces that it has today launched a programme to purchase ordinary shares of 2 pence each in IP Group ("Ordinary Shares") up to an aggregate consideration of £35 million (the "Buyback Programme").

 

As previously announced and consistent with its Capital Allocation Policy, the Group's Board has specifically reserved up to £35 million for share buybacks. In light of the Group's prevailing share price, notwithstanding recent portfolio events, and consistent with its commitment to shareholder returns, the Board has determined that now is the appropriate time to formally launch the Buyback Programme.

 

The Group has entered into a non-discretionary arrangement with Numis to manage the Buyback Programme and repurchase Ordinary Shares on its behalf and within certain parameters, including to only buy back Ordinary Shares at a discount to Hard NAV per share. The Buyback Programme will run from the date of this announcement to 31 March 2022, unless terminated earlier. Numis will make its trading decisions in relation to the Ordinary Shares independently of the Group. 

Purchases of Ordinary Shares pursuant to the Buyback Programme will take place in open market transactions and may be made from time-to-time depending on market conditions, the Group's share price, trading volumes in the Group's Ordinary Shares and other factors. The maximum price paid per Ordinary Share will be: (A) no more than the higher of: (i) 5 per cent above the average of the middle market quotations taken from the London Stock Exchange Daily Official List for the five business days preceding any ordinary shares being purchased; and (ii) the price of the last independent trade and the highest independent bid for Ordinary Shares on the trading venue where the purchase is carried out; and (B) no less than (exclusive of expenses) a price of 2 pence per Ordinary Share, being the nominal value of an Ordinary Share. Under the Buyback Programme, any Ordinary Shares purchased will be held in treasury.

The Buyback Programme is in accordance with IP Group's general authority to purchase a maximum of 106,253,373 Ordinary Shares, granted by its shareholders at the Annual General Meeting held on 9 June 2021. The Buyback Programme will also be effected within the parameters of the Market Abuse Regulation 596/2014/EU and the Commission Delegated Regulation 2016/1052/EU (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), including where relevant pursuant to the Market Abuse (Amendment)(EU Exit) Regulations 2019), and in accordance with Chapter 12 of the Financial Conduct Authority's Listing Rules. IP Group confirms that it currently has no other unpublished price sensitive information.

IP Group will make further regulatory announcements to shareholders in respect of purchases of Ordinary Shares by the Group as they occur.

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7979 853802

Charlotte Street Partners

David Gaffney

+44 (0) 7854 609998

Andrew Wilson

+44 (0) 7810 636995

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFDLLBFBLXFBD
Date   Source Headline
15th Jan 20253:21 pmRNSForm 8.3 - Tissue Regenix Group plc
15th Jan 20257:00 amRNSTransaction in Own Shares
14th Jan 20257:00 amRNSTransaction in Own Shares
10th Jan 20256:02 pmRNSTransaction in Own Shares
10th Jan 20257:00 amRNSTransaction in Own Shares
9th Jan 20257:00 amRNSShare buyback programme update
8th Jan 20257:00 amRNSTransaction in Own Shares
6th Jan 20255:43 pmRNSTransaction in Own Shares
31st Dec 20247:00 amRNSTotal Voting Rights
20th Dec 20245:09 pmRNSTransaction in Own Shares
20th Dec 20241:46 pmRNSForm 8.3 - Intelligent Ultrasound Group plc
20th Dec 20247:00 amRNS-RTwo life sciences companies receive cash offers
20th Dec 20247:00 amRNSTransaction in Own Shares
19th Dec 20241:10 pmRNS£119m initial cash after sale of Featurespace
18th Dec 20246:26 pmRNSTransaction in Own Shares
18th Dec 20247:00 amRNSTransaction in Own Shares
16th Dec 20244:55 pmRNSTransaction in Own Shares
13th Dec 20245:59 pmRNSTransaction in Own Shares
13th Dec 20247:00 amRNSTransaction in Own Shares
12th Dec 20247:00 amRNSAGM post-meeting shareholder engagement update
12th Dec 20247:00 amRNSTransaction in Own Shares
11th Dec 20247:00 amRNSTransaction in Own Shares
10th Dec 20247:00 amRNSTransaction in Own Shares
9th Dec 20242:44 pmRNSHolding(s) in Company
9th Dec 202412:00 pmRNSHolding(s) in Company
9th Dec 20247:00 amRNSSecondary sale of minority holdings in portfolio
6th Dec 20245:13 pmRNSTransaction in Own Shares
6th Dec 20241:57 pmRNSForm 8.3 - Tissue Regenix Group plc
6th Dec 20247:00 amRNSTransaction in Own Shares
3rd Dec 20245:18 pmRNSTransaction in Own Shares
3rd Dec 20247:00 amRNSTransaction in Own Shares
2nd Dec 20241:35 pmRNSHolding(s) in Company
2nd Dec 20247:01 amRNSTotal Voting Rights
2nd Dec 20247:00 amRNSTransaction in Own Shares
29th Nov 20247:00 amRNSTransaction in Own Shares
27th Nov 20246:16 pmRNSTransaction in Own Shares
27th Nov 20247:00 amRNSTransaction in Own Shares
25th Nov 20246:09 pmRNSTransaction in Own Shares
25th Nov 20247:00 amRNSTransaction in Own Shares
22nd Nov 20247:00 amRNSTransaction in Own Shares
21st Nov 20247:00 amRNSTransaction in Own Shares
20th Nov 20247:00 amRNSTransaction in Own Shares
19th Nov 20247:00 amRNSTransaction in Own Shares
15th Nov 20245:59 pmRNSTransaction in Own Shares
15th Nov 20248:45 amRNSForm 8.3 - Tissue Regenix Group plc
15th Nov 20247:00 amRNSTransaction in Own Shares
13th Nov 20245:10 pmRNSTransaction in Own Shares
13th Nov 20247:00 amRNSTransaction in Own Shares
12th Nov 20247:00 amRNSTransaction in Own Shares
8th Nov 20245:17 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.